With TrumpRx launching this week, immediately bringing down the costs of America’s new favorite medication, GLP-1, the knock-off merchants are surely panicking. Hims and Hers will spend millions of dollars during America’s other favorite medication, the Super Bowl, to hawk a new concierge service rooted in left-wing populism.

Predictably, the ad only uses white actors for the scenes depicting the out-of-touch, moneyed elite, while every scene about ordinary people has an ethnic minority portraying America. But in Hims’ case, that’s beside the point.

The firm that was referred to the Department of Justice today, and its commercial has rightly raised eyebrows for its use of Galleri cancer detection, which “missed more cases of cancer than it found,” according to Eric Topol, director of the Scripps Research Translational Institute.

Based on a review of the applicable facts, earlier today @HHSOGC referred Hims & Hers Health, Inc. (“Hims”) to the Department of Justice for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.

— HHS General Counsel Mike Stuart (@HHSGCMikeStuart) February 6, 2026

Voiced by ‘conscious rapper’ Common, who himself is worth a very uncommon $20 million, the ad implies Hims and Hers will be the Robin Hood of the healthcare industry, giving ordinary people access to things only rich people (like Common) have.

Rich people get concierge IV drips, customized peptides, preventative care, and specialists on call. And you’ll basically get the exact same thing if you download their app! Except you won’t. You’ll get what companies like Hims are really good at providing: cheap knockoffs and left-wing politics.

“It’s all about democratizing access to the things that are available to the super rich, and we’re bringing them to people,” said Hims’ chief design officer, Dan Kenger.

It is no surprise the ad copy sounds like it was written by a Bernie Sanders staffer. It probably was.

Hims’ CEO Andrew Dudum is a repeat donor to members of the far-left “squad” or “Justice Democrats” such as illegal immigrant Ilhan Omar, Islamist loudmouth Rashida Tlaib, as well as Joe Biden, Kamala Harris, and Cori Bush. His list of political donations makes for very interesting reading, and of course concludes with the same Bernie Sanders he’s seeking to channel in Hims’ Super Bowl ad.

Last year, Dudum offered to hire “Gaza Solidarity” protesters after writing about the “Nakba” – an Arabic term for the “catastrophe” of the founding of the State of Israel, on his Medium page. The company famously lost almost $210 million in stock value after his woke tweet.

“As a father whose children are both the descendants of Palestinian refugees who fled the Nakba in 1948, and the descendants of Holocaust survivors from Poland, I have a deep consideration for nuance in my life,” Dudum wrote in 2023.

If only he had deep consideration for the nuances in the world of medicine.

The centerpiece of the ad campaign is a new $49 oral semaglutide pill. It is positioned as an alternative to Novo Nordisk’s Wegovy pill, which launched just weeks ago after years of development, testing, and regulatory review. Novo’s product relies on a patented system designed to protect the active ingredient during digestion and ensure absorption.

Hims does not have that patent, nor do they disclose how their pill survives the digestive process.

They are effectively launching a product using an unproven technology, with no publicly available evidence that the active ingredient is even bioavailable.

Novo’s CEO, Mike Doustdar, was blunt in his reaction. “You’re wasting $49, in my opinion,” he said, explaining that Novo’s patents exist precisely because protecting semaglutide through digestion is the hard part.

Some biotech investors have labeled Hims’ product a “scam.” Hims is effectively conducting a mass experiment without transparency, regulatory approval, or proof of effectiveness, and laundering their untested pharmaceutical behavior through the Super Bowl and a ‘conscious’ (read: woke) Grammy-winning rapper.

Trump-appointed FDA Commissioner Marty Makary issued a pointed warning on Thursday, writing on X: “FDA will take swift action against companies mass-marketing illegal copycat drugs, claiming they are similar to FDA-approved products.”

Hims doesn’t disclose where it sources its active pharmaceutical ingredients. The company says they come from “FDA registered” facilities, but registration is not approval. When a drug itself lacks FDA approval, sourcing becomes even more important.

As we have previously noted, much of the knockoff drug supply chain runs through China, where quality control and oversight are persistent concerns. American consumers have no way of knowing what they are taking or whether it will have any effect.

In practice, Hims is selling leftist populism using America’s collective waistline as its hook. They’re quite explicit about it, in fact, with Kenger telling Variety: “There’s probably going to be a lot of weight loss commercials this year, and they’re probably going to try to be funny and they’re probably going to be relatable and they’re probably going to have a celebrity, right? And that’s great,” he says. “I think we’re past that conversation. You know, we did that. We talked about it. The prices are down. Now let’s talk about something else.”

That “something else” appears to be peddling a pill with no track record of success. Thankfully, the TrumpRx launch this week means fewer Americans will risk whatever it is Hims is putting in its knockoff Wegovy.